A phase II open-label study of vandetanib in patients with locally advanced or metastatic hereditary medullary thyroid cancerRobert I. Haddad, Benjamin M. Robinson, Luis Paz‐Ares et al.|Journal of Clinical Oncology|2008Cited by 37